Dyne Therapeutics Inc
DYN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.37B
Close$
$6.80
62.4% downside
Current Fair Value
62.4% downsideOvervalued by 62.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.37 Billion |
|---|---|
| Enterprise Value | $2.71 Billion |
| Earnings per Share | $-3.47 |
| Beta | 1.21 |
| Outstanding Shares | 181,765,918 |
Return
| Return on Equity | -64.98% |
|---|---|
| Return on Assets | -48.99% |
| Return on Invested Capital | -51.49% |
Valuation & Multiples
| P/E Ratio | -4.98 |
|---|---|
| PEG | -6.29 |
| Price to Sales | - |
| Price to Book Ratio | 3.61 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.59 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.26 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.91
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 1, 2027
EPS Estimate
$-0.88
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 421.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.47%▼ 115.76% |
|---|---|
| Total Invested | $12.49M▼ 99.71% |
| Investors Holding | 44▼ 210.00% |
About Dyne Therapeutics Inc
47 employees
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.